![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Dynavax Issues Positive Phase III Results for Hepatitis Vaccine Heplisav-b
Dynavax Issues Positive Phase III Results for Hepatitis Vaccine Heplisav-b
Dynavax has published subgroup results from the pivotal Phase III trial of its investigational hepatitis B vaccine, Heplisav-b.
The clinical analysis demonstrated that Heplisav-b, when administered as two doses over one month, brought significantly higher seroprotection rates than the approved hepatitis B vaccine Engerix-B, when administered as three doses over six months.
The study compared two doses of Heplisav-b over four weeks with three doses of Engerix-B over 24 weeks in 8,374 adults age 18 to 70.
Upcoming Events
-
21Oct